Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Alemtuzumab MeSH Descriptor Data 2026


MeSH Heading
Alemtuzumab
Tree Number(s)
D12.776.124.486.485.114.224.060.313
D12.776.124.790.651.114.224.060.375
D12.776.377.715.548.114.224.200.375
Unique ID
D000074323
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000074323
Scope Note
An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.
Entry Term(s)
Campath
Campath 1G
Campath 1H
Campath 1M
Campath-1-G
Campath-1G
Campath-1H
Campath-1M
Lemtrada
MabCambath
Monoclonal Antibody Campath-1H
Pharm Action
Antineoplastic Agents, Immunological
Registry Numbers
3A189DH42V
0
See Also
CD52 Antigen
Public MeSH Note
2018; ALEMTUZUMAB was indexed under ANTIBODIES, MONOCLONAL, 1995-2011 and under ANTIBODIES, MONOCLONAL, HUMANIZED, 2012-2017
History Note
2018 (1995)
Date Introduced
2018/01/01
Last Updated
2018/01/01
Alemtuzumab Preferred
Campath 1M Narrower
Campath 1G Narrower
Campath Narrower
MabCambath Narrower
Lemtrada Narrower
Campath 1H Narrower
page delivered in 0.152s